©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 7 Issue 1 Page 118-123, 2026

https://doi.org/10.59298/NIJRMS/2026/7.1.118123

Nanotherapeutics Targeting Mitochondrial Dysfunction in Obesity and Type 2 Diabetes

Nalongo Bina K.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Mitochondrial dysfunction is a critical feature of both obesity and type 2 diabetes (T2D), contributing to metabolic abnormalities such as insulin resistance, oxidative stress, and impaired energy metabolism. The mitochondria, being central to cellular energy production and regulation, play a key role in the development of insulin resistance and other complications associated with obesity. Traditional therapeutic approaches have failed to directly address mitochondrial dysfunction. However, nanotechnology provides a promising avenue for targeted delivery of therapeutics aimed at restoring mitochondrial function. This review explores the role of mitochondria in obesity and T2D, the potential of nanotherapeutics to modulate mitochondrial activity, and the challenges and prospects of these innovative treatments in clinical practice. By focusing on mitochondria-targeted therapies, we outline how nanotechnology can provide new solutions for treating obesity-induced insulin resistance and improving metabolic health.

Keywords: nanotherapeutics, mitochondrial dysfunction, obesity, type 2 diabetes, insulin resistance

INTRODUCTION

Obesity and type 2 diabetes (T2D) are two of the most prevalent and rapidly growing metabolic disorders worldwide, with their incidence increasing at an alarming rate[1–3]. Both conditions are associated with insulin resistance, a state in which the body's tissues, particularly muscle, liver, and adipose tissue, become less responsive to insulin[2, 4–6]. This results in impaired glucose uptake and metabolism, contributing to hyperglycemia, hyperinsulinemia, and disrupted lipid metabolism. In addition to insulin resistance, obesity and T2D are linked to chronic low-grade inflammation, oxidative stress, and mitochondrial dysfunction, which together exacerbate disease progression[7–9].

Mitochondria are the cell's powerhouses, responsible for producing energy in the form of adenosine triphosphate (ATP) through oxidative phosphorylation[10]. They also regulate critical cellular processes such as apoptosis, calcium homeostasis, and reactive oxygen species (ROS) production. In healthy individuals, mitochondria efficiently convert nutrients into ATP, maintain cellular energy balance, and modulate metabolic pathways[10]. However, in the context of obesity and T2D, mitochondrial function is often impaired due to various factors such as increased fatty acid oxidation, accumulation of toxic byproducts, and mitochondrial DNA damage[11]. This mitochondrial dysfunction contributes to the development of insulin resistance by disrupting energy production, increasing ROS generation, and impairing mitochondrial biogenesis and mitophagy (the process of removing damaged mitochondria)[11].

One of the primary mechanisms through which mitochondrial dysfunction contributes to insulin resistance is increased oxidative stress. In obesity and T2D, excess nutrients (primarily glucose and fatty acids) are processed by the mitochondria, leading to the overproduction of ROS[12, 13]. These highly reactive molecules damage cellular components, including proteins, lipids, and DNA, contributing to inflammation and insulin signaling disruption[12, 14]. Furthermore, the accumulation of damaged mitochondria in insulin-sensitive tissues exacerbates metabolic dysfunction, leading to insulin resistance and reduced glucose uptake by muscle and liver cells.

Given the critical role of mitochondria in metabolic regulation, restoring mitochondrial function is a promising therapeutic strategy for managing obesity and T2D. Traditional treatments for insulin resistance and obesity primarily focus on improving insulin sensitivity through lifestyle modifications, oral medications, and insulin

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

therapy. However, these approaches do not directly address the underlying mitochondrial dysfunction that contributes to disease progression[15]. Nanotechnology offers an innovative solution by enabling the targeted delivery of therapeutic agents to the mitochondria, where they can restore mitochondrial function, reduce oxidative stress, and improve metabolic outcomes.

Nanotherapeutics, which utilize nanoparticles (NPs) to deliver bioactive compounds, have gained significant attention for their ability to target specific cellular compartments, such as the mitochondria[16]. Nanoparticles can be engineered to improve the solubility, stability, and bioavailability of drugs, allowing for efficient drug delivery to the mitochondria and other intracellular targets[16]. Mitochondria-targeted nanotherapeutics have the potential to restore mitochondrial function by delivering antioxidants, anti-inflammatory agents, and agents that promote mitochondrial biogenesis or mitophagy. Moreover, nanoparticles can be designed to carry genetic material such as mRNA or siRNA that can modulate mitochondrial gene expression, further enhancing the therapeutic potential[16].

This review will explore the role of mitochondrial dysfunction in obesity and T2D, the potential of nanotherapeutics in targeting mitochondrial dysfunction, and the mechanisms through which nanoparticles can restore mitochondrial health. We will also discuss the challenges of translating these therapies into clinical practice and the future directions for research in this area.

2. Mitochondrial Dysfunction in Obesity and Type 2 Diabetes

Mitochondrial dysfunction is a central factor in the pathogenesis of obesity and type 2 diabetes (T2D)[17]. Both conditions are characterized by insulin resistance, a metabolic disorder where insulin's ability to regulate blood glucose is impaired. Insulin resistance is often accompanied by disrupted mitochondrial function, leading to a vicious cycle that exacerbates the development of metabolic diseases[18].

Mitochondrial Dysfunction and Insulin Resistance

Mitochondria play a crucial role in maintaining energy homeostasis by facilitating the oxidation of fatty acids and glucose metabolism. In a healthy individual, mitochondria generate ATP through oxidative phosphorylation, using glucose and fatty acids as substrates. However, in obesity and T2D, the accumulation of excess nutrients, particularly free fatty acids and glucose, overwhelms the mitochondria, leading to several key dysfunctions[19].

One of the primary mechanisms through which mitochondrial dysfunction contributes to insulin resistance is the overproduction of reactive oxygen species (ROS). In a state of metabolic overload, mitochondria produce excessive ROS, which can damage mitochondrial DNA (mtDNA), proteins, and lipids[20]. This oxidative stress leads to inflammation and impairs insulin signaling pathways in insulin-sensitive tissues, such as the liver, muscle, and adipose tissue. Elevated ROS levels also inhibit the insulin receptor substrate (IRS) proteins, key regulators of insulin signaling, further worsening insulin resistance[20].

Moreover, mitochondrial dysfunction can impair mitochondrial biogenesis and mitophagy, processes that are essential for maintaining a healthy population of mitochondria[21]. In obesity and T2D, the failure to remove damaged mitochondria and generate new, functional mitochondria contributes to the accumulation of dysfunctional mitochondria in insulin-sensitive tissues[21]. This further disrupts metabolic processes and contributes to insulin resistance and hyperglycemia.

Mitochondrial Dysfunction and Inflammation

Another critical aspect of mitochondrial dysfunction in obesity and T2D is its role in promoting chronic low-grade inflammation. Excessive ROS production from dysfunctional mitochondria activates the nuclear factor-kappa B (NF-κB) pathway, leading to the release of pro-inflammatory cytokines, such as TNF-α, IL-6, and CRP[22]. These cytokines further exacerbate insulin resistance by impairing insulin signaling in peripheral tissues. Chronic inflammation also increases the infiltration of macrophages and other immune cells into adipose tissue, leading to inflammatory adipokine secretion that disrupts insulin sensitivity[22].

The inflammatory response driven by mitochondrial dysfunction also contributes to lipotoxicity, a condition in which the accumulation of free fatty acids in non-adipose tissues (such as muscle and liver) leads to insulin resistance and hepatic steatosis (fatty liver disease)[22]. Lipotoxicity further impairs mitochondrial function and accelerates the progression of obesity-related metabolic diseases.

3. Nanotherapeutic Approaches to Target Mitochondrial Dysfunction

Nanotherapeutics represent a novel and promising approach to targeting mitochondrial dysfunction in obesity and type 2 diabetes (T2D). Nanoparticles (NPs) are engineered materials, typically ranging in size from 1 to 100 nm, that can be designed to deliver therapeutic agents directly to mitochondria, restoring mitochondrial function and improving metabolic outcomes[23, 24]. The unique properties of NPs, such as their small size, high surface area, and biocompatibility, allow them to cross biological barriers and target intracellular structures, including mitochondria.

Antioxidant Nanoparticles

One of the most promising applications of nanotechnology in mitochondrial therapeutics is the delivery of antioxidants to combat oxidative stress[25, 26]. As mitochondrial dysfunction is often characterized by excessive ROS production, the use of antioxidants can help neutralize these reactive species and protect

mitochondrial function. Nanoparticles can be engineered to encapsulate antioxidants such as coenzyme Q10 (CoQ10), curcumin, or vitamin E, allowing for enhanced stability and bioavailability[27, 28].
For instance, lipid-based nanoparticles have been used to deliver CoQ10, a critical antioxidant that is involved in mitochondrial electron transport and ATP production. CoQ10 supplementation has been shown to reduce ROS production, improve mitochondrial efficiency, and enhance insulin sensitivity in obese and diabetic animal models[29]. Similarly, curcumin-loaded nanoparticles have been shown to reduce oxidative stress and inflammation in the liver and adipose tissue, leading to improved glucose metabolism and insulin sensitivity.

Mitochondrial Biogenesis and Mitophagy
In addition to reducing oxidative stress, nanotherapeutic approaches can promote mitochondrial biogenesis and enhance mitophagy to restore mitochondrial health. Polymeric nanoparticles loaded with resveratrol, a natural compound that activates sirtuins (SIRT1), have been shown to stimulate mitochondrial biogenesis and improve mitochondrial function in metabolic tissues[30]. Resveratrol activates the AMP-activated protein kinase (AMPK) pathway, which promotes mitochondrial energy production and enhances insulin sensitivity[31–34].
Similarly, nanoparticles that deliver PINK1 or Parkin, key regulators of mitophagy, can enhance the removal of damaged mitochondria and improve overall mitochondrial function[35]. Targeting mitophagy is particularly important in obesity and T2D, as impaired mitophagy contributes to the accumulation of dysfunctional mitochondria, further exacerbating insulin resistance.
Gene Delivery Nanoparticles
Another promising approach is the use of gene delivery nanoparticles to restore mitochondrial function by modulating mitochondrial gene expression. mRNA-based nanoparticles can deliver specific mitochondrial-targeted genes or proteins that are deficient or damaged in obesity and T2D[36]. For example, nanoparticles can be used to deliver mitochondrial DNA (mtDNA) or genes encoding mitochondrial enzymes, such as ATP synthase or Cox1, to enhance mitochondrial function[36].
Gene delivery using nanoparticles can also be applied to activate mitochondrial pathways involved in energy metabolism, such as PPARs (peroxisome proliferator-activated receptors), which regulate fatty acid oxidation and mitochondrial efficiency[36].
4. Challenges and Future Perspectives
While nanotherapeutics targeting mitochondrial dysfunction hold great promise in managing obesity and type 2 diabetes (T2D), several challenges must be addressed before these therapies can be widely applied in clinical practice[37].
Biocompatibility and Safety
The biocompatibility and safety of nanoparticles are critical factors for their clinical application. Nanoparticles must be designed to avoid toxicity and immune responses in the body[38]. The accumulation of nanoparticles in non-target tissues, particularly in the liver and kidneys, could lead to unwanted side effects or long-term toxicity. Therefore, extensive preclinical studies are required to evaluate the long-term safety of mitochondrial-targeted nanoparticles[38].
Targeting Specificity
One of the major challenges in developing effective nanotherapeutics is ensuring their specificity for mitochondria. Mitochondria are highly dynamic organelles, and targeting them with high precision requires careful design of nanoparticles that can selectively bind to mitochondrial membranes and avoid off-target interactions[39]. Targeting moieties, such as mitochondrial targeting sequences (MTS) or lipophilic cations, must be incorporated into the nanoparticles to ensure their efficient delivery to the mitochondria.
Scalability and Manufacturing
The large-scale production of nanoparticles with consistent quality and functionality remains a significant hurdle. The scalability of nanoparticle production processes must be optimized to meet clinical demands while maintaining reproducibility and uniformity. Additionally, ensuring the stability of nanoparticles in biological environments and during storage is crucial for their practical use[40].
Clinical Translation
Although preclinical studies have shown promising results, translating mitochondrial-targeted nanotherapeutics into clinical practice requires overcoming regulatory challenges. The clinical validation of these therapies through rigorous clinical trials is essential to demonstrate their efficacy and safety in humans[41]. Furthermore, the cost-effectiveness of these therapies must be evaluated to ensure that they are accessible and feasible for widespread clinical use.
Future Directions
Future research should focus on developing multi-functional nanoparticles that can simultaneously target mitochondrial dysfunction, reduce oxidative stress, and improve insulin sensitivity. The integration of gene editing technologies with nanotherapeutic platforms could also open new avenues for personalized treatments targeting mitochondrial DNA defects. Additionally, exploring the combination of mitochondrial-targeted therapies with other treatments, such as anti-inflammatory agents or nutraceuticals, could enhance the overall therapeutic efficacy for obesity and T2D management.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

CONCLUSION

Mitochondrial dysfunction is a key feature of obesity and type 2 diabetes (T2D) that contributes to insulin resistance, oxidative stress, and metabolic dysregulation. Traditional treatments for these metabolic disorders do not directly address the underlying mitochondrial dysfunction. However, nanotherapeutics offer a promising solution by enabling targeted delivery of therapeutic agents that restore mitochondrial function, reduce oxidative stress, and improve insulin sensitivity. Nanoparticles can be engineered to deliver antioxidants, mitochondrial biogenesis stimulators, and gene therapies that enhance mitochondrial health. By targeting mitochondria directly, these nanotherapies hold the potential to correct metabolic dysfunction at its source, offering a more effective treatment for obesity and T2D. However, challenges such as biocompatibility, targeting specificity, and clinical translation must be addressed before these therapies can be widely implemented in clinical practice.

In conclusion, nanotechnology holds immense potential in the fight against obesity and type 2 diabetes by targeting mitochondrial dysfunction. As research advances, the integration of nanotherapeutics into clinical care could offer new hope for personalized, effective treatments that address the root causes of metabolic diseases and improve patient outcomes.

REFERENCES

1. Holmes, A., Coppey, L.J., Davidson, E.P., Yorek, M.A.: Rat Models of Diet-Induced Obesity and High Fat/Low Dose Streptozotocin Type 2 Diabetes: Effect of Reversal of High Fat Diet Compared to Treatment with Enalapril or Menhaden Oil on Glucose Utilization and Neuropathic Endpoints. J. Diabetes Res. 2015, 307285 (2015). https://doi.org/10.1155/2015/307285
2. Patra, D., Banerjee, D., Ramprasad, P., Roy, S., Pal, D., Dasgupta, S.: Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes. Front. Mol. Biosci. 10, 1224982 (2023). https://doi.org/10.3389/fmolb.2023.1224982
3. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
4. Różańska-Walędziak, A., Walędziak, M.: Unraveling the Complexity of Metabolic Disorders Through Biomarkers: A Focus on Obesity and Type 2 Diabetes Mellitus. Biomedicines. 13, 2443 (2025). https://doi.org/10.3390/biomedicines13102443
5. Acevedo-Román, A., Pagán-Zayas, N., Velázquez-Rivera, L.I., Torres-Ventura, A.C., Godoy-Vitorino, F.: Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches. Int. J. Mol. Sci. 25, 9715 (2024). https://doi.org/10.3390/ijms25179715
6. Anand, S., Patel, T.N.: Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review. Discov. Oncol. 15, 779 (2024). https://doi.org/10.1007/s12672-024-01662-1
7. Bansal, S.K., Bansal, M.B.: Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity. Aliment. Pharmacol. Ther. 59, S10–S22 (2024). https://doi.org/10.1111/apt.17930
8. Bensussen, A., Torres-Magallanes, J.A., Roces De Álvarez-Buylla, E.: Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 14, 1014778 (2023). https://doi.org/10.3389/fimmu.2023.1014778
9. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
10. Cooper, G.M.: Mitochondria. In: The Cell: A Molecular Approach. 2nd edition. Sinauer Associates (2000)
11. Qin, B., Wang, Y., Ding, J.: The role of mitochondrial function in the pathogenesis of diabetes. Front. Endocrinol. 16, 1607641 (2025). https://doi.org/10.3389/fendo.2025.1607641
12. Bhatti, J.S., Bhatti, G.K., Reddy, P.H.: Mitochondrial dysfunction and oxidative stress in metabolic disorders - A Step towards mitochondria based therapeutic strategies. Biochim. Biophys. Acta. 1863, 1066–1077 (2017). https://doi.org/10.1016/j.bbadis.2016.11.010
13. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diab. Vasc. Dis. Res. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
14. Alum, E.U., Uti, D.E., Offor, C.E.: Redox Signaling Disruption and Antioxidants in Toxicology: From Precision Therapy to Potential Hazards. Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01846-8
15. Masenga, S.K., Kabwe, L.S., Chakulya, M., Kirabo, A.: Mechanisms of Oxidative Stress in Metabolic Syndrome. Int. J. Mol. Sci. 24, 7898 (2023). https://doi.org/10.3390/ijms24097898
16. Wang, S.-H., Xu, X.-L., Chen, W.: How Do Organelle-Targeting Nanotherapeutics Treat Inflammatory Diseases? A Comprehensive Review of the Literature. Int. J. Nanomedicine. 20, 7133–7152 (2025). https://doi.org/10.2147/IJN.S516260

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

17. Pinti, M.V., Fink, G.K., Hathaway, Q.A., Durr, A.J., Kunovac, A., Hollander, J.M.: Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. Am. J. Physiol. - Endocrinol. Metab. 316, E268–E285 (2019). https://doi.org/10.1152/ajpendo.00314.2018
18. Li, X., Chen, W., Jia, Z., Xiao, Y., Shi, A., Ma, X.: Mitochondrial Dysfunction as a Pathogenesis and Therapeutic Strategy for Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci. 26, 4256 (2025). https://doi.org/10.3390/ijms26094256
19. Wadan, A.-H.S., Moshref, A.S., Emam, A.M., Bakry, Y.G., Khalil, B.O., Chaurasia, A., Ibrahim, R.A.H., Badawy, T., Mehanny, S.S.: Mitochondrial dysfunction as a key player in aggravating periodontitis among diabetic patients: review of the current scope of knowledge. Naunyn. Schmiedebergs Arch. Pharmacol. 398, 13173–13204 (2025). https://doi.org/10.1007/s00210-025-04025-x
20. Sergi, D., Naumovski, N., Heilbronn, L.K., Abeywardena, M., O'Callaghan, N., Lionetti, L., Luscombe-Marsh, N.: Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet. Front. Physiol. 10, 532 (2019). https://doi.org/10.3389/fphys.2019.00532
21. Yildirim, R.M., Ergun, Y., Basar, M.: Mitochondrial Dysfunction, Mitophagy and Their Correlation with Perinatal Complications: Preeclampsia and Low Birth Weight. Biomedicines. 10, 2539 (2022). https://doi.org/10.3390/biomedicines10102539
22. Marino, F., Petrella, L., Cimmino, F., Pizzella, A., Monda, A., Allocca, S., Rotondo, R., D'Angelo, M., Musco, N., Iommelli, P., Catapano, A., Bagnato, C., Paolini, B., Cavaliere, G.: From Obesity to Mitochondrial Dysfunction in Peripheral Tissues and in the Central Nervous System. Biomolecules. 15, 638 (2025). https://doi.org/10.3390/biom15050638
23. Keethedeth, N., Anantha Shenoi, R.: Mitochondria-targeted nanotherapeutics: A new frontier in neurodegenerative disease treatment. Mitochondrion. 81, 102000 (2025). https://doi.org/10.1016/j.mito.2024.102000
24. Nag, S., Mitra, O., Maturi, B., Kaur, S.P., Saini, A., Nama, M., Roy, S., Samanta, S., Chacko, L., Dutta, R., Sayana, S.B., Subramaniyan, V., Bhatti, J.S., Kandimalla, R.: Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics. Asian J. Pharm. Sci. 19, 100927 (2024). https://doi.org/10.1016/j.ajps.2024.100927
25. De, U., Ij, A., Eu, A., E, N., Un, O., I, B., Sa, A., Ci, U., Ge, E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, (2025). https://doi.org/10.1186/s11671-025-04248-0
26. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
27. Liu, Q., Sun, Y., Cui, Q., Cheng, J., Killpartrik, A., Kemp, A.H., Guo, M.: Characterization, antioxidant capacity, and bioaccessibility of Coenzyme Q10 loaded whey protein nanoparticles. LWT. 160, 113258 (2022). https://doi.org/10.1016/j.lwt.2022.113258
28. Quagliariello, V., Vecchione, R., De Capua, A., Lagreca, E., Iaffaioli, R.V., Botti, G., Netti, P.A., Maurea, N.: Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab. Int. J. Nanomedicine. 15, 4859–4876 (2020). https://doi.org/10.2147/IJN.S245170
29. Zahedi, H., Eghtesadi, S., Seifirad, S., Rezaee, N., Shidfar, F., Heydari, I., Golestan, B., Jazayeri, S.: Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial. J. Diabetes Metab. Disord. 13, 81 (2014). https://doi.org/10.1186/s40200-014-0081-6
30. Soukar, J., Singh, K.A., Aviles, A., Hargett, S., Kaur, H., Foster, S., Roy, S., Zhao, F., Gohil, V.M., Singh, I., Gaharwar, A.K.: Nanomaterial-induced mitochondrial biogenesis enhances intercellular mitochondrial transfer efficiency. Proc. Natl. Acad. Sci. U. S. A. 122, e2505237122. https://doi.org/10.1073/pnas.2505237122
31. Li, Z., Zhang, Z., Ke, L., Sun, Y., Li, W., Feng, X., Zhu, W., Chen, S.: Resveratrol promotes white adipocytes browning and improves metabolic disorders in Sirt1-dependent manner in mice. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 34, 4527–4539 (2020). https://doi.org/10.1096/fj.201902222R
32. Sikur, N., Böröczky, C., Paszternák, A., Gyöngyössy, R., Szökő, É., Varga, K., Tábi, T.: Resveratrol and Its Derivatives Diminish Lipid Accumulation in Adipocytes In Vitro—Mechanism of Action and Structure–Activity Relationship. Nutrients. 16, 3869 (2024). https://doi.org/10.3390/nu16223869
33. Trofin, A.-M., Scripcariu, D.V., Filipiuc, S.-I., Neagu, A.-N., Filipiuc, L.-E., Tamba, B.-I., Palaghia, M.M., Uritu, C.M.: From Nature to Nanomedicine: Enhancing the Antitumor Efficacy of Rhein, Curcumin, and Resveratrol. Medicina (Mex.). 61, 981 (2025). https://doi.org/10.3390/medicina61060981
34. Wang, W., Zhou, M., Xu, Y., Peng, W., Zhang, S., Li, R., Zhang, H., Zhang, H., Cheng, S., Wang, Y., Wei, X., Yue, C., Yang, Q., Chen, C.: Resveratrol-Loaded TPGS-Resveratrol-Solid Lipid Nanoparticles for

Multidrug-Resistant Therapy of Breast Cancer: In Vivo and In Vitro Study. Front. Bioeng. Biotechnol. 9, 762489 (2021). https://doi.org/10.3389/fbioe.2021.762489

35. González, L.F., Bevilacqua, L.E., Naves, R.: Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases. Pharmaceutics. 13, 2055 (2021). https://doi.org/10.3390/pharmaceutics13122055
36. Buchke, S., Sharma, M., Bora, A., Relekar, M., Bhanu, P., Kumar, J.: Mitochondria-Targeted, Nanoparticle-Based Drug-Delivery Systems: Therapeutics for Mitochondrial Disorders. Life. 12, 657 (2022). https://doi.org/10.3390/life12050657
37. Luo, X., Li, N., Zhu, X., Xie, W., Zhang, Q., Liang, N., Zhang, P., Zhou, C.: Application of nanomaterials in diabetic complication management. Colloids Surf. B Biointerfaces. 258, 115229 (2026). https://doi.org/10.1016/j.colsurfb.2025.115229
38. Nikzamir, M., Akbarzadeh, A., Panahi, Y.: An overview on nanoparticles used in biomedicine and their cytotoxicity. J. Drug Deliv. Sci. Technol. 61, 102316 (2021). https://doi.org/10.1016/j.jddst.2020.102316
39. Li, Y., Li, X., Wei, L., Ye, J.: Advancements in mitochondrial-targeted nanotherapeutics: overcoming biological obstacles and optimizing drug delivery. Front. Immunol. 15, (2024). https://doi.org/10.3389/fimmu.2024.1451989
40. Vinukonda, A., Bolledla, N., Jadi, R.K., Chinthala, R., Devadasu, V.R.: Synthesis of nanoparticles using advanced techniques. Nanotechnol. 8, 100169 (2025). https://doi.org/10.1016/j.nxnano.2025.100169
41. Joshi, D.C., Prasad, S., Bhati, V., Sharma, P.K., Joshi, N., Durgapal, S., Chavan, M.B., Maurya, V.K., Subramaniyan, V., Paudel, K.R., Gupta, M.: Revolutionizing cancer treatment: Nanotherapeutics targeting the tumor micro-environment. Colloids Surf. B Biointerfaces. 258, 115204 (2026). https://doi.org/10.1016/j.colsurfb.2025.115204

CITE AS: Nalongo Bina K. (2026). Nanotherapeutics Targeting Mitochondrial Dysfunction in Obesity and Type 2 Diabetes. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. https://doi.org/10.59298/NIJRMS/2026/7.1.118123